Stock Scorer

Avenue Therapeutics, Inc. (ATXI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 500K 1M 1.5M Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 1.4M Q3 '25: 0 Q4 '25: 0 Q2 '26: 0 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q2 '26

Operating Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '21: -872K Q4 '21: -914K Q1 '22: -2.9M Q2 '22: -605K Q3 '22: -663K Q4 '22: -3.9M Q1 '23: -6.4M Q2 '23: -3.9M Q3 '23: -2.1M Q4 '23: -2.1M Q1 '24: -3.7M Q2 '24: -2.8M Q3 '24: -3.2M Q4 '24: -1.6M Q1 '25: -1.9M Q2 '25: 297K Q3 '25: -724K Q4 '25: -752K Q1 '26: -714K Q2 '26: -707K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '21: -871K Q4 '21: -913K Q1 '22: -2.9M Q2 '22: -604K Q3 '22: -662K Q4 '22: 575K Q1 '23: -7.6M Q2 '23: -4M Q3 '23: 526K Q4 '23: 595K Q1 '24: -4.3M Q2 '24: -2.7M Q3 '24: -3.1M Q4 '24: -1.5M Q1 '25: -1.9M Q2 '25: 335K Q3 '25: -683K Q4 '25: -709K Q1 '26: -695K Q2 '26: -690K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '21: -536K Q4 '21: -1.2M Q1 '22: -1.9M Q2 '22: -943K Q3 '22: -554K Q4 '22: -4.2M Q1 '23: -1.6M Q2 '23: -4.7M Q3 '23: -889K Q4 '23: -2.3M Q1 '24: -3.1M Q2 '24: -2.3M Q3 '24: -2.9M Q4 '24: -764K Q1 '25: -1.2M Q2 '25: -176K Q3 '25: 383K Q4 '25: -854K Q1 '26: -438K Q2 '26: -475K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Shares Outstanding Quarterly

0 8M 16M 24M Q3 '20: 16.5M Q1 '21: 16.6M Q2 '21: 16.6M Q3 '21: 1.1M Q1 '22: 21M Q2 '22: 21.9M Q3 '22: 1.5M Q1 '23: 74.2K Q2 '23: 103.4K Q3 '23: 8.2M Q1 '24: 562K Q2 '24: 1.1M Q3 '24: 1.6M Q1 '25: 3M Q2 '25: 3.2M Q3 '25: 3.2M Q1 '26: 3.3M Q2 '26: 3.3M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-75.00 -50.00 -25.00 0.00 25.00 50.00 75.00 Q3 '19: -1.76 Q4 '19: -1.72 Q1 '20: -0.98 Q2 '20: -0.66 Q3 '20: -0.58 Q4 '20: -0.31 Q1 '21: -0.29 Q2 '21: -0.24 Q3 '21: -0.97 Q4 '23: -73.48 Q1 '24: 12.69 Q2 '24: 45.00 Q3 '24: 43.02 Q4 '24: -15.79 Q1 '25: -1.01 Q2 '25: 5.53 Q3 '25: 7.24 Q4 '25: -0.94 Q1 '26: -0.53 Q2 '26: -0.85 Q4 '19 Q3 '20 Q2 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ATXI: Gross Profit, Cost of Revenue, Free Cash Flow. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.